Corrigendum to 'The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017' [Eur J Canc 145 (2021) 11–18]

Autor: Anthony Gonçalves, Marc A. Rodwin, Patricia Marino, Julien Mancini, Patrice Viens, Dominique Maraninchi, Ségolène Duran, Anne-Céline Jalbert

Publikováno v: European Journal of Cancer
European Journal of Cancer, 2021, 152, pp.259-261. ⟨10.1016/j.ejca.2021.04.018⟩

International audience; No abstract available

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25719cecec98c833e39f86d1ef691ec1
https://doi.org/10.1016/j.ejca.2021.04.018

Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer

Autor: Louis Tassy, Joëlle Micallef, Maria Paciencia, Maud Cecile, Annie-Pierre Jonville-Béra, Ségolène Duran, Frédérique Rousseau, Franck Rouby, Emanuel Nicolas, Anne Madroszyk, Renaud Sabatier, Cecile Braticevic

Publikováno v: Journal of Geriatric Oncology
Journal of Geriatric Oncology, 2018, 9 (5), pp.494-500. ⟨10.1016/j.jgo.2018.02.011⟩
Journal of Geriatric Oncology, Elsevier, 2018, 9 (5), pp.494-500. ⟨10.1016/j.jgo.2018.02.011⟩

Background: Nivolumab is approved worldwide as second-line treatment for metastatic non-small cell lung cancer (NSCLC). Despite the fact that most of these cancers are being diagnosed in the older patients, few of the patients were included in pivota

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9a64c91b4ec25899c65ed760cf2833
https://amu.hal.science/hal-02143604

Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy

Autor: Patrizia Carrieri, Dominique Peyramond, Jean-Marie Lang, Catherine Leport, Christine Katlama, Bruno Spire, Geneviève Chêne, Jean-Paul Moatti, Ségolène Duran, Cécile Francois

Publikováno v: JAIDS Journal of Acquired Immune Deficiency Syndromes. 32:38-47

Objective: We investigated the impact of the first year of highly active antiretroviral therapy (HAART) on health-related quality of life (HRQL). Methods: Medical data for patients in the French APROCO cohort were collected at enrollment (M0) and mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d242571673288a1c0732a88c21bf6eb4
https://doi.org/10.1097/00126334-200301010-00006

Impact of Discontinuation of Initial Protease Inhibitor Therapy on Further Virological Response in a Cohort of Human Immunodeficiency Virus–Infected Patients

Autor: Ségolène Duran, Charlotte Lewden, Catherine Leport, Vincent Le Moing, Franæois Raffi, Bernard Masquelier, Geneviève Chêne, Michel Dupon, Michel Garré

Publikováno v: Clinical Infectious Diseases. 34:239-247

Although discontinuation of antiretroviral drug therapy is common, the impact on outcome in routine clinical practice is unknown. The Antiproteases Cohorte (APROCO) Cohort Study enrolled 1281 patients at the time they started a protease inhibitor (PI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29afacc6c71f1a5ba6e6973035d744dd
https://doi.org/10.1086/324354

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

Autor: Sylvain, Garciaz, Diane, Coso, Frederic, Peyrade, Sabine, Fürst, Ségolène, Duran, Bruno, Chetaille, Isabelle, Brenot-Rossi, Raynier, Devillier, Angela, Granata, Didier, Blaise, Réda, Bouabdallah

Publikováno v: Hematological oncology. 32(4)

Patients with relapsed or refractory Hodgkin lymphoma (RR-HL) have poor outcomes. Brentuximab vedotin (BV), an antibody-drug conjugate comprising an anti-CD30 antibody conjugated to the potent anti-microtubule agent, monomethyl auristatin E, induces

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ce0ec33bc29099bb677c771598db37d4
https://pubmed.ncbi.nlm.nih.gov/24301099